Full-Time

NPI Sourcing Senior Manager

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Chennai, Tamil Nadu, India

Remote

Bachelor's, Master's, MBA

Category
Operations & Logistics (1)
Required Skills
Agile
Inventory Management
Forecasting
SAP Products

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Highly proficient in MS Office products and ERP systems, preferably SAP and Agile
  • Working knowledge of Kanban systems and other Lean material handling methods
  • Detailed knowledge of supply chain & sourcing strategies
  • Detailed knowledge of material planning, master scheduling and forecasting
  • Detailed knowledge of global and regional manufacturing
  • Minimum BS degree or equivalent
  • BE, B.Tech, MS
  • 8+ years of experience in purchasing management with emphasis in new product environment for high complexity product
  • 5+ years of management experience with medium size manufacturing organization
Responsibilities
  • Select, train, develop, and manage commodity managers, buyers and program managers across various disciplines from R&D procurement through supply chain product launch stabilization
  • Create strategies to benefit the company in the near term to 5+ years in the future
  • Lead and support new product cost targets, project milestone dates
  • Review and identify suppliers that will be integral in our mission to expanding minimally invasive care to an ever growing population
  • Lead supplier engagements for the organization and our cross functional stakeholders
  • Apply critical skills to identify and employ strategies to effectively meet product and project cost goals, identify supply risk, and evaluate supplier performance
  • Work with cross­ functional teams on the evaluation of suppliers and provide guidance to commodity managers on the effectiveness of current strategies
  • Efforts to continuously improve time to market, a critical measurement for Intuitive
  • Ability to create flexible processes to help new product requirements, and make effective recommendations using limited information
  • Ensure that optimal inventory levels of commodities are established to meet production launch requirements
  • Meet quick turn requirements for new product development deadlines
  • Speed the entire process including PO placement, supplier delivery performance, cost studies, spend examination, new supplier selection, and cost negotiations is necessary to help time to market
  • Ensure continued compliance to Purchasing SOP’s, DOP’s and SOX requirements
  • Establish and achieve new product Purchasing Departmental Goals
  • Set standards for productivity improvements by effectively deploy process improvement and work standardization
  • Mentor commodity managers, program managers and buyers to successfully perform job tasks and provide ongoing coaching and development
  • Employ supply chain management best practices to secure uninterrupted supply
  • Identify alternatives for “high risk” suppliers that could jeopardize product launch goals
  • Lead and drive contract negotiations and document creation, provide feedback to development teams regarding effectiveness of new suppliers (risk, cost, delivery, quality). Develop key supplier relationships to effectively launch new products
  • Implement Short-Term Problem Containment and Long-Term Corrective Action for Shortages and other process related issues
  • Oversee supplier new product forecast communication to ensure short and long term visibility is available for supplier capacity and delivery planning
  • Create supply chain strategies with materials team for new products; work with cross functional team to approve new key suppliers
Desired Qualifications
  • MBA
  • BE/B.tech

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 19% to $2.89 billion, beating estimates again.
  • Intuitive raised 2026 da Vinci procedure growth guidance to 13.5%-15.5%.
  • Asia-Pacific demand supports Penang operations starting 2028 and 1,200 jobs by 2032.

What critics are saying

  • FDA Class II recalls in 2026 hit da Vinci X, Xi, and SP components.
  • US da Vinci growth slowed to 12% in Q2 2026, signaling elective-procedure deferral.
  • Medtronic's Hugo and other robotic entrants erode Intuitive's pricing power by 2027.

What makes Intuitive Surgical unique

  • Da Vinci 5 deepens Intuitive Surgical's installed-base moat; Q2 2026 placements hit 468.
  • Recurring instruments and accessories drove 85% of Q2 2026 revenue, stabilizing cash generation.
  • Penang facility in Malaysia expands manufacturing resilience for da Vinci instruments and electromechanical devices.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.

Yahoo Finance
Aug 16th, 2026
Oppenheimer upgrades Intuitive Surgical to 'Outperform' with $500 price target

Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" with a $500 price target, implying a 24.6% upside. The analysts expect the medtech company to maintain its leading position in robotic surgery despite increasing competition. Intuitive reported strong Q2 results, with revenue rising 18.5% year-over-year to $2.89 billion, surpassing analyst expectations. Non-GAAP earnings per share climbed 27.9% to $2.80, beating the $2.50 estimate. The company placed 468 da Vinci surgical systems and 55 Ion endoluminal systems during the quarter. Combined da Vinci and Ion procedures rose approximately 16% globally. Wall Street maintains a "Strong Buy" consensus rating on the stock, with 22 of 31 analysts recommending a strong buy. The consensus price target of $480.93 represents a 19.85% upside.

Yahoo Finance
Aug 12th, 2026
Intuitive Surgical's valuation barely budges despite two years of growth forecasts

Intuitive Surgical trades at $401.23, down 32% from its 52-week high and 15% over twelve months. The stock currently trades at 37.7 times trailing adjusted earnings. Analysts forecast earnings of $12.08 per share by 2027, bringing the multiple down to 33 times — only 13% lower despite two years of growth. Consensus projects 7% annual earnings growth and 9.7% revenue growth, suggesting margin compression ahead. Management raised its 2026 gross profit margin guidance to 68-69%. However, the company plans to extend instrument use limits starting in the first half of 2027 to lower procedure costs and boost adoption. Intuitive has not finalised pricing for this programme, creating uncertainty around 2027 estimates. The company will quantify the impact on its next earnings call.